Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus TRANCOPAL.
ORPHENADRINE CITRATE vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties. Its exact mechanism of action is not fully understood, but it is believed to exert its effects by blocking muscarinic acetylcholine receptors and possibly by acting as an NMDA receptor antagonist. It may also have local anesthetic and antihistaminic properties.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
100 mg orally twice daily. Maximum: 250 mg/day.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Terminal elimination half-life is approximately 14 hours (range 11–20 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Primarily renal excretion of metabolites; less than 10% excreted unchanged. Also undergoes biliary excretion with fecal elimination of conjugates.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant